Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Intestinal2466 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A03784 | 33865013 | Biomed Pharmacother | Salvia-Nelumbinis naturalis extract protects mice against MCD diet-induced steatohepatitis via activation of colonic FXR-FGF15 pathway. | 2021 | Details |
| A03820 | 33857511 | Int J Biol Macromol | Walnut green husk polysaccharides prevent obesity, chronic inflammatory responses, nonalcoholic fatty liver disease and colonic tissue damage in high-fat diet fed rats. | 2021 | Details |
| A03842 | 33851592 | Wiad Lek | THE ROLE OF ZONULIN IN THE DEVELOPMENT OF LIVER FIBROSIS IN OBESE ADOLESCENTS. | 2021 | Details |
| A03846 | 33849107 | Ann Palliat Med | Qinghua Fang inhibits high-fat diet-induced non-alcoholic fatty liver disease by modulating gut microbiota. | 2021 | Details |
| A03847 | 33849075 | Nucleic Acids Res | iNetModels 2.0: an interactive visualization and database of multi-omics data. | 2021 | Details |
| A03895 | 33829368 | Adv Ther | Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management. | 2021 | Details |
| A03928 | 33815296 | Front Endocrinol (Lausanne) | Cardio-Metabolic Indices and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors. | 2021 | Details |
| A03932 | 33813462 | Wiad Lek | RATIO OF MAIN PHYLOTYPES OF GUT MICROBIOTA IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE DEPENDING ON THE BODY MASS INDEX. | 2021 | Details |
| A03940 | 33811372 | J Gastroenterol Hepatol | Gut-liver-axis: Barrier function of liver sinusoidal endothelial cell. | 2021 | Details |
| A03952 | 33809593 | Nutrients | Fortifying Butterfat with Soybean Oil Attenuates the Onset of Diet-Induced Non-Alcoholic Steatohepatitis and Glucose Intolerance. | 2021 | Details |
| A03958 | 33808007 | Int J Mol Sci | Momordica cochinchinensis Aril Ameliorates Diet-Induced Metabolic Dysfunction and Non-Alcoholic Fatty Liver by Modulating Gut Microbiota. | 2021 | Details |
| A03962 | 33807605 | Int J Mol Sci | Mechanisms by Which Probiotic Bacteria Attenuate the Risk of Hepatocellular Carcinoma. | 2021 | Details |
| A03986 | 33801023 | Nutrients | Characterization of Gut Microbiome in Korean Patients with Metabolic Associated Fatty Liver Disease. | 2021 | Details |
| A04019 | 33787507 | Dis Model Mech | Modulation of serotonin in the gut-liver neural axis ameliorates the fatty and fibrotic changes in non-alcoholic fatty liver. | 2021 | Details |
| A04044 | 33777700 | Toxicol Rep | Polychlorinated biphenyls altered gut microbiome in CAR and PXR knockout mice exhibiting toxicant-associated steatohepatitis. | 2021 | Details |
| A04058 | 33773656 | Food Res Int | Dietary anthocyanins as potential natural modulators for the prevention and treatment of non-alcoholic fatty liver disease: A comprehensive review. | 2021 | Details |
| A04060 | 33773192 | Phytomedicine | Si Miao Formula attenuates non-alcoholic fatty liver disease by modulating hepatic lipid metabolism and gut microbiota. | 2021 | Details |
| A04080 | 33767591 | Int J Biol Sci | Understanding the Effects of Gut Microbiota Dysbiosis on Nonalcoholic Fatty Liver Disease and the Possible Probiotics Role: Recent Updates. | 2021 | Details |
| A04087 | 33765728 | Clin Endosc | Fecal Microbiota Transplantation beyond Clostridioides Difficile Infection. | 2021 | Details |
| A04098 | 33761609 | Biomed Pharmacother | Ethyl pyruvate supplemented in drinking water ameliorates experimental nonalcoholic steatohepatitis. | 2021 | Details |
| A04106 | 33755449 | J Agric Food Chem | Gut Microbiota and Its Metabolite Deoxycholic Acid Contribute to Sucralose Consumption-Induced Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A04170 | 33729777 | J Agric Food Chem | Dietary Polyphenols to Combat Nonalcoholic Fatty Liver Disease via the Gut-Brain-Liver Axis: A Review of Possible Mechanisms. | 2021 | Details |
| A04192 | 33721354 | Clin Exp Pharmacol Physiol | Sodium butyrate ameliorates non-alcoholic fatty liver disease by upregulating miR-150 to suppress CXCR4 expression. | 2021 | Details |
| A04200 | 33718398 | Front Med (Lausanne) | Oxidative Stress in Non-alcoholic Fatty Liver Disease. An Updated Mini Review. | 2021 | Details |
| A04202 | 33716495 | Curr Treat Options Gastroenterol | An update on the role of the microbiome in non-alcoholic fatty liver disease pathogenesis, diagnosis, and treatment. | 2020 | Details |
| A04203 | 33716447 | World J Gastroenterol | G protein-coupled receptors as potential targets for nonalcoholic fatty liver disease treatment. | 2021 | Details |
| A04221 | 33709477 | J Gastroenterol Hepatol | Gut microbiota composition associated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver disease. | 2021 | Details |
| A04227 | 33707081 | Best Pract Res Clin Endocrinol Metab | Gut microbiome and bile acids in obesity-related diseases. | 2021 | Details |
| A04231 | 33705945 | J Nutr Biochem | High sucrose diet-induced dysbiosis of gut microbiota promotes fatty liver and hyperlipidemia in rats. | 2021 | Details |
| A04237 | 33693900 | J Nutr | Consumption of High-Fructose Corn Syrup Compared with Sucrose Promotes Adiposity and Increased Triglyceridemia but Comparable NAFLD Severity in Juvenile Iberian Pigs. | 2021 | Details |
| A04238 | 33693866 | J Nutr | Hepatoprotective Effects of Indole, a Gut Microbial Metabolite, in Leptin-Deficient Obese Mice. | 2021 | Details |
| A04280 | 33679051 | J Clin Exp Hepatol | Successful Outcome of Bariatric Surgery in Living Donor Liver Transplant Recipients With Multidisciplinary Approach: A Preliminary Experience. | 2020 | Details |
| A04284 | 33678110 | Gut Microbes | Akkermansia muciniphila and environmental enrichment reverse cognitive impairment associated with high-fat high-cholesterol consumption in rats. | 2022 | Details |
| A04285 | 33678036 | Hum Exp Toxicol | Early intervention with probiotics and metformin alleviates liver injury in NAFLD rats via targeting gut microbiota dysbiosis and p-AKT/mTOR/LC-3II pathways. | 2021 | Details |
| A04293 | 33674694 | Sci Rep | DSS-induced colitis is associated with adipose tissue dysfunction and disrupted hepatic lipid metabolism leading to hepatosteatosis and dyslipidemia in mice. | 2021 | Details |
| A04297 | 33672887 | Toxins (Basel) | Fungi-Bacteria Correlation in Alcoholic Hepatitis Patients. | 2021 | Details |
| A04327 | 33664710 | Front Endocrinol (Lausanne) | Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis. | 2021 | Details |
| A04332 | 33664007 | Arab J Gastroenterol | Short-term orlistat therapy improves fatty infiltration indices and liver fibrosis scores in patients with non-alcoholic fatty liver disease and metabolic syndrome. | 2021 | Details |
| A04344 | 33657386 | Cell Metab | Proton pump inhibitor use status does not modify the microbiome signature for cirrhosis. | 2021 | Details |
| A04352 | 33652261 | Biomed Pharmacother | Akebia saponin D ameliorates metabolic syndrome (MetS) via remodeling gut microbiota and attenuating intestinal barrier injury. | 2021 | Details |
| A04353 | 33651661 | Gut Microbes | Links between gut microbiome composition and fatty liver disease in a large population sample. | 2022 | Details |
| A04386 | 33639194 | Eur J Pharmacol | Research progress in use of traditional Chinese medicine monomer for treatment of non-alcoholic fatty liver disease. | 2021 | Details |
| A04391 | 33637088 | Lipids Health Dis | Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients: a systematic review and Meta-analysis. | 2021 | Details |
| A04394 | 33636349 | Pharmacol Res | Current innovations in nutraceuticals and functional foods for intervention of non-alcoholic fatty liver disease. | 2021 | Details |
| A04406 | 33630750 | Eur J Endocrinol | MECHANISMS IN ENDOCRINOLOGY: FXR signalling: a novel target in metabolic diseases. | 2021 | Details |
| A04410 | 33629536 | Mol Nutr Food Res | Effect of Mastiha supplementation on NAFLD: The MAST4HEALTH Randomised, Controlled Trial. | 2021 | Details |
| A04420 | 33622853 | mSystems | Impaired Intestinal Akkermansia muciniphila and Aryl Hydrocarbon Receptor Ligands Contribute to Nonalcoholic Fatty Liver Disease in Mice. | 2021 | Details |
| A04423 | 33622213 | Am J Chin Med | Intestinal Flora: A Pivotal Role in Investigation of Traditional Chinese Medicine. | 2021 | Details |
| A04440 | 33615993 | Gut Microbes | Modulation of the PI3K/Akt/mTOR signaling pathway by probiotics as a fruitful target for orchestrating the immune response. | 2022 | Details |
| A04456 | 33609303 | Hepatology | Microbiota-Driven Activation of Intrahepatic B Cells Aggravates NASH Through Innate and Adaptive Signaling. | 2021 | Details |
| A04472 | 33603757 | Front Immunol | Extracellular Vesicles as Inflammatory Drivers in NAFLD. | 2021 | Details |
| A04479 | 33601216 | Nutr Res | G protein-coupled receptors: Key molecules in metabolic associated fatty liver disease development. | 2020 | Details |
| A04489 | 33598160 | Food Sci Nutr | The protective effect of sulforaphane on type II diabetes induced by high-fat diet and low-dosage streptozotocin. | 2020 | Details |
| A04492 | 33597157 | Gut | Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial. | 2021 | Details |
| A04537 | 33584555 | Front Microbiol | The Therapeutic Efficacy of Curcumin vs. Metformin in Modulating the Gut Microbiota in NAFLD Rats: A Comparative Study. | 2021 | Details |
| A04555 | 33581174 | J Hepatol | A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis. | 2021 | Details |
| A04569 | 33577920 | J Hepatol | Diagnosis and management of secondary causes of steatohepatitis. | 2021 | Details |
| A04596 | 33569476 | Ann Transl Med | A narrative review of the roles of indoleamine 2,3-dioxygenase and tryptophan-2,3-dioxygenase in liver diseases. | 2021 | Details |
| A04600 | 33567710 | Int J Environ Res Public Health | Nutritional Approach Targeting Gut Microbiota in NAFLD-To Date. | 2021 | Details |
| A04617 | 33561650 | Biomed Pharmacother | The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD. | 2021 | Details |
| A04618 | 33561256 | J Nutr | Dietary Fruit and Vegetable Supplementation Suppresses Diet-Induced Atherosclerosis in LDL Receptor Knockout Mice. | 2021 | Details |
| A04619 | 33560577 | Mol Nutr Food Res | Three Novel Dietary Phenolic Compounds from Pickled Raphanus Sativus L. Inhibit Lipid Accumulation in Obese Mice by Modulating the Gut Microbiota Composition. | 2021 | Details |
| A04623 | 33559369 | Mol Nutr Food Res | Black Current Anthocyanins Improve Lipid Metabolism and Modulate Gut Microbiota in High-Fat Diet-Induced Obese Mice. | 2021 | Details |
| A04654 | 33550112 | Redox Biol | Citrulline supplementation attenuates the development of non-alcoholic steatohepatitis in female mice through mechanisms involving intestinal arginase. | 2021 | Details |
| A04663 | 33548123 | J Gastrointestin Liver Dis | Vegan Diet Advice Might Benefit Liver Enzymes in Nonalcoholic Fatty Liver Disease: an Open Observational Pilot Study. | 2021 | Details |
| A04668 | 33546191 | Biomedicines | Insights into the Impact of Microbiota in the Treatment of NAFLD/NASH and Its Potential as a Biomarker for Prognosis and Diagnosis. | 2021 | Details |
| A04678 | 33544906 | Hepatology | De Novo Colorectal and Pancreatic Cancer in Liver-Transplant Recipients: Identifying the Higher-Risk Populations. | 2021 | Details |
| A04681 | 33544313 | Hepatol Int | Regression of portal hypertension: underlying mechanisms and therapeutic strategies. | 2021 | Details |
| A04693 | 33538526 | Gastroenterol Nurs | Gut Microbiome and Nonalcoholic Fatty Liver Disease (NAFLD): Implications for Nursing Care of Individuals Living With Chronic Metabolic Diseases. | 2021 | Details |
| A04728 | 33525625 | Molecules | The Protective Role of Butyrate against Obesity and Obesity-Related Diseases. | 2021 | Details |
| A04736 | 33520569 | Biosci Microbiota Food Health | Correlation of gut Firmicutes/Bacteroidetes ratio with fibrosis and steatosis stratified by body mass index in patients with non-alcoholic fatty liver disease. | 2020 | Details |
| A04757 | 33513826 | Nutrients | Editorial "Nutrition and Dietary Intake for Liver-Related Diseases". | 2021 | Details |
| A04763 | 33513397 | Life Sci | The influence of PM2.5 exposure on non-alcoholic fatty liver disease. | 2021 | Details |
| A04788 | 33505393 | Front Immunol | Role of Metabolic Endotoxemia in Systemic Inflammation and Potential Interventions. | 2021 | Details |
| A04793 | 33505139 | World J Gastroenterol | Gut microbiota mediated molecular events and therapy in liver diseases. | 2020 | Details |
| A04822 | 33493657 | Pharmacol Res | Baicalin and the liver-gut system: Pharmacological bases explaining its therapeutic effects. | 2021 | Details |
| A04830 | 33491316 | Obesity (Silver Spring) | Fecal Fungi Dysbiosis in Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A04833 | 33490737 | Hepatoma Res | Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease. | 2021 | Details |
| A04840 | 33488295 | Mediators Inflamm | Associations among Dietary Omega-3 Polyunsaturated Fatty Acids, the Gut Microbiota, and Intestinal Immunity. | 2021 | Details |
| A04849 | 33485064 | Biomed Pharmacother | Crosstalk between PPARs and gut microbiota in NAFLD. | 2021 | Details |
| A04854 | 33482026 | Aliment Pharmacol Ther | Cross-linkage between bacterial taxonomy and gene functions: a study of metagenome-assembled genomes of gut microbiota in adult non-alcoholic fatty liver disease. | 2021 | Details |
| A04869 | 33474981 | AJR Am J Roentgenol | Utility of Multiparametric CT for Identification of High-Risk NAFLD. | 2021 | Details |
| A04874 | 33471632 | Am J Physiol Gastrointest Liver Physiol | Bacterial and eukaryotic extracellular vesicles and nonalcoholic fatty liver disease: new players in the gut-liver axis? | 2021 | Details |
| A04931 | 33445719 | Int J Environ Res Public Health | Mortality Risk and Decompensation in Hospitalized Patients with Non-Alcoholic Liver Cirrhosis: Implications for Disease Management. | 2021 | Details |
| A04934 | 33444725 | J Ethnopharmacol | Anti-NAFLD effect of defatted walnut powder extract in high fat diet-induced C57BL/6 mice by modulating the gut microbiota. | 2021 | Details |
| A04983 | 33426540 | J Cell Immunol | Maternal Diet Alters Trained Immunity in the Pathogenesis of Pediatric NAFLD. | 2020 | Details |
| A04999 | 33420074 | Nat Commun | Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma. | 2021 | Details |
| A05003 | 33417955 | Life Sci | Sacran, a sulfated polysaccharide, suppresses the absorption of lipids and modulates the intestinal flora in non-alcoholic steatohepatitis model rats. | 2021 | Details |
| A05009 | 33411984 | J Appl Microbiol | The interplay between host cellular and gut microbial metabolism in NAFLD development and prevention. | 2021 | Details |
| A05023 | 33407877 | Biol Sex Differ | Analysis of sex differences in dietary copper-fructose interaction-induced alterations of gut microbial activity in relation to hepatic steatosis. | 2021 | Details |
| A05026 | 33406286 | Int J Clin Pract | Small intestinal bacterial overgrowth and non-alcoholic fatty liver disease diagnosed by transient elastography and liver biopsy. | 2021 | Details |
| A05031 | 33401222 | Biomed Pharmacother | Pure total flavonoids from citrus attenuate non-alcoholic steatohepatitis via regulating the gut microbiota and bile acid metabolism in mice. | 2021 | Details |
| A05034 | 33400402 | J Cell Mol Med | Val-Val-Tyr-Pro protects against non-alcoholic steatohepatitis in mice by modulating the gut microbiota and gut-liver axis activation. | 2021 | Details |
| A05037 | 33398776 | Hepatol Int | Elobixibat, an ileal bile acid transporter inhibitor, ameliorates non-alcoholic steatohepatitis in mice. | 2021 | Details |
| A05038 | 33398223 | J Clin Exp Hepatol | Effect of COVID-19 on Pre-existing Liver disease: What Hepatologist Should Know? | 2020 | Details |
| A05047 | 33395434 | PLoS One | Modeling dysbiosis of human NASH in mice: Loss of gut microbiome diversity and overgrowth of Erysipelotrichales. | 2021 | Details |
| A05088 | 33382431 | J Nutr | Polylactose Exhibits Prebiotic Activity and Reduces Adiposity and Nonalcoholic Fatty Liver Disease in Rats Fed a High-Fat Diet. | 2021 | Details |
| A05094 | 33378966 | Biomed Pharmacother | Potential effects of SARS-CoV-2 on the gastrointestinal tract and liver. | 2020 | Details |
| A05096 | 33378048 | Eur Rev Med Pharmacol Sci | Gut microbiota and its metabolic potential. | 2020 | Details |
| A05118 | 33369197 | Mol Nutr Food Res | Punicalagin Prevents Hepatic Steatosis through Improving Lipid Homeostasis and Inflammation in Liver and Adipose Tissue and Modulating Gut Microbiota in Western Diet-Fed Mice. | 2021 | Details |